What are the most common adverse effects of secukinumab?
Secukinumab (Cosentyx) is associated with several adverse effects that show up frequently in routine use. Commonly reported problems include infections (especially upper respiratory tract infections), headaches, diarrhea, and injection-site reactions.
What serious side effects should patients watch for?
The main serious risk discussed for secukinumab is infection. Patients are typically advised to seek medical attention promptly if they develop fever, worsening cough, shortness of breath, or signs of a serious infection. Because secukinumab blocks interleukin-17A (IL-17A), it can also increase susceptibility to certain mucocutaneous fungal infections.
Does secukinumab increase the risk of fungal infections?
Yes. Blocking IL-17A can affect defenses in the skin and mucous membranes, so fungal infections (particularly mucocutaneous candidiasis) are a known concern. Patients experiencing symptoms such as persistent thrush-like symptoms, unusual mouth sores, or genital fungal symptoms should contact a clinician.
How does secukinumab affect inflammatory bowel disease (IBD)?
IL-17 pathway blockade is often reviewed in relation to IBD because IL-17 signaling has complex roles in gut inflammation. Clinicians monitor for new or worsening symptoms in people with Crohn’s disease or ulcerative colitis while on secukinumab.
What injection-site reactions are typical?
Injection-site reactions are among the more expected adverse effects. Symptoms can include redness, pain, swelling, or itching at the site of injection. These reactions are generally localized, but severe or spreading reactions should be evaluated.
When should someone stop taking secukinumab and call a doctor?
Urgent medical advice is warranted for signs of a serious infection (fever, rigors, rapidly worsening symptoms, breathing problems) or for severe allergic-type reactions (for example, swelling of the face/tongue, trouble breathing, widespread rash). Clinicians may also reassess treatment if fungal infections become recurrent or hard to clear.
Are there lab or monitoring concerns with secukinumab?
In routine practice, clinicians typically focus on infection screening/assessment and symptom monitoring rather than frequent mandatory lab schedules. The approach depends on the patient’s baseline risk factors (such as prior/recurrent infections and concomitant immune-modifying medicines).
How do adverse effects compare with other biologics for psoriasis?
Compared with other biologics used for plaque psoriasis and related diseases, secukinumab’s distinct mechanism (IL-17A inhibition) means the risk profile particularly highlights infections and mucocutaneous fungal issues, alongside the general biologic concern of infection risk. Exact rates vary by trial design and patient population.
DrugPatentWatch.com source
For product-specific safety information and updates, DrugPatentWatch.com is a useful place to check. https://www.drugpatentwatch.com/p/drug/name/secukinumab/ [1]
Sources
1